Now we are evaluating surface markers of TILs in EGFR wild-type NSCLC patients to clarify whether the density of CD4+ T cells and Foxp3+ T cells is correlated with the efficacy of anti-PD-1/PD-L1 treatment. The gene discussed is FOXP3; the disease is non-small cell lung carcinoma.